Welcome to our dedicated page for Teladoc Health SEC filings (Ticker: TDOC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Teladoc Health filings document the company’s virtual care operations, financial reporting, governance structure, equity compensation practices, and common-stock matters. Recent Form 8-K reports furnish quarterly and annual results releases, including segment disclosures for Integrated Care and BetterHelp, adjusted EBITDA measures, outlook commentary, and cash-flow information.
The company’s proxy and current reports also disclose board composition, director appointments and retirements, audit, compensation, and nominating and corporate governance committee assignments, director independence determinations, and non-employee director compensation arrangements. Other filings cover amendments to the 2023 Employment Inducement Incentive Award Plan, shares reserved for issuance, inducement awards, Regulation FD exhibits, and related governance disclosures under NYSE and SEC rules.
Teladoc Health insider plans to sell recently vested shares. A holder has filed notice to sell 17,138 shares of Teladoc Health common stock through Fidelity Brokerage Services on or about 12/11/2025, with an aggregate market value of $130,836.63. The filing notes that 177,473,405 Teladoc shares were outstanding, giving context for the size of this planned sale.
The 17,138 shares to be sold were acquired on 12/10/2025 via restricted stock vesting as compensation from the issuer. The same seller, Charles Divita, previously sold 16,787 Teladoc common shares on 09/11/2025 for gross proceeds of $127,435.15. By signing the notice, the seller represents that he is not aware of undisclosed material adverse information about Teladoc’s operations.
Teladoc Health, Inc. insider equity activity: A company officer, the President of BetterHelp, reported multiple stock transactions in early December 2025. On December 1, 2025, the officer exercised restricted stock units that converted on a one-for-one basis into 5,491 shares of Teladoc common stock and an additional 1,042 shares, both at an exercise price of $0, reflecting vesting of prior equity awards.
On December 2, 2025, the officer sold 2,324 shares of common stock at $7.488 per share to cover tax withholding obligations related to the vesting. On December 3, 2025, a further 4,209 shares were sold at $7.48 per share pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2024 and amended on November 27, 2024. Following these transactions, the form shows remaining holdings in restricted stock units, including 21,966 and 5,210 units from prior grants that continue to vest over time.
Teladoc Health’s chief legal officer and secretary reported routine stock activity related to vesting of prior equity awards. On December 1, 2025, 1,505 performance stock units and two blocks of restricted stock units (4,418 and 5,350 units) converted on a one-for-one basis into shares of Teladoc common stock. On December 2, 2025, 5,720 common shares were sold at $7.488 per share to satisfy tax withholding obligations tied to these vesting events. After these transactions, the officer directly owns 80,732 shares of common stock and continues to hold derivative awards, including performance and restricted stock units scheduled to vest over time.
Teladoc Health insider equity activity: A Teladoc Health officer, identified as President, International, reported routine equity compensation transactions involving company common stock. On December 1, 2025, the officer acquired 1,056 shares of Teladoc common stock through performance stock units converting on a one-for-one basis and an additional 3,101 shares and 4,556 shares through restricted stock units that also convert one-for-one into common stock. These awards stem from prior grants made in March 2023 and March 2024 with scheduled vesting over time.
On December 2, 2025, the officer sold 3,897 shares of Teladoc common stock at a price of $7.488 per share to cover tax withholding obligations related to the vesting of the performance and restricted stock units. Following these transactions, the officer continued to hold tens of thousands of Teladoc shares directly, reflecting ongoing equity ownership linked to prior stock unit grants.
Teladoc Health, Inc. officer reports stock unit vesting and tax-sale transaction. A Teladoc Health executive, serving as President, U.S. Group Health, reported the conversion of performance stock units and restricted stock units into common stock and a related sale of shares.
On 12/01/2025, 1,189 performance stock units and two blocks of restricted stock units totaling 8,346 units (3,488 and 4,858) converted into the same number of Teladoc common shares on a one-for-one basis. On 12/02/2025, 4,582 shares of common stock were sold at $7.488 per share to cover tax withholding obligations from these vestings.
After these transactions, the reporting person beneficially owned 60,054 shares of Teladoc common stock directly, along with remaining derivative holdings that include performance and restricted stock units scheduled to vest over time under prior grants.
TDOC insider Fernando Madeira Rodrigues filed a Form 144 to sell 4,209 common shares. The planned sale, with aggregate market value of 31,483.32, is to be executed through Fidelity Brokerage Services LLC on the NYSE around 12/03/2025. The issuer has 177,473,405 shares of common stock outstanding. These 4,209 shares were acquired on 12/01/2025 through restricted stock vesting from the issuer as compensation.
Over the prior three months, the same seller reported two additional sales of the issuer’s common stock: 4,149 shares on 09/03/2025 for gross proceeds of 31,490.91 and 2,324 shares on 12/02/2025 for gross proceeds of 17,402.81.
A shareholder filed a Rule 144 notice to sell 5,720 common shares of the issuer associated with symbol TDOC. The planned sale is to be executed through Fidelity Brokerage Services LLC on the NYSE on or about 12/02/2025, with an indicated aggregate market value of $42,833.07. The filing notes that there are 177,473,405 shares outstanding.
The 5,720 shares to be sold were acquired on 12/01/2025 through restricted stock vesting from the issuer as compensation. The notice also discloses that the same insider sold 5,867 common shares on 09/02/2025 for gross proceeds of $44,502.95. By signing, the seller represents that they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
Teladoc Health insider plans sale of recently vested shares. A holder of Teladoc Health common stock filed a notice of proposed sale covering 3,897 shares to be sold through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 12/02/2025. These shares were acquired on 12/01/2025 through restricted stock vesting from the issuer as compensation. The filing notes that 177,473,405 shares of Teladoc Health common stock were outstanding. It also reports that the same seller disposed of 3,998 common shares on 09/02/2025 for gross proceeds of $30,326.03. The seller represents that they are not aware of undisclosed material adverse information about the company.
An affiliate of the company with symbol TDOC has filed a Rule 144 notice indicating an intent to sell 4,582 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of 34,311.39. The filing notes that 177,473,405 shares of the issuer’s stock were outstanding at the time of the notice; this is a baseline figure, not the amount being sold.
The shares to be sold were acquired on 12/01/2025 via restricted stock vesting from the issuer as compensation, with payment recorded on the same date. The notice also reports that in the past three months, the same seller, identified as Kelly Bliss, sold 4,700 common shares on 09/02/2025 for gross proceeds of 35,650.91.
A shareholder of TDOC has filed a Form 144 notice to sell 2,324 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $17,402.81. The shares are part of a much larger base of 177,473,405 common shares outstanding.
The stock to be sold was acquired on 12/01/2025 through restricted stock vesting from the issuer as compensation. The same seller previously sold 2,383 and 4,149 common shares on 09/02/2025 and 09/03/2025, generating gross proceeds of $18,075.77 and $31,490.91. By signing the notice, the seller represents they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.